Related Experiment Videos
Piperacillin therapy for Pseudomonas infections
Abstract:
Piperacillin, a new broad spectrum semisynthetic penicillin derivative, was administered to 22 patients with 25 Pseudomonas aeruginosa infections. All initially responded favorably, although five complicated urinary tract infections and two infections involving prostheses relapsed. In 15 cases, microbiologic eradication of the Pseudomonas was achieved. Failure to achieve a clinical cure was correlated in all cases with the inability to eradicate the organism, which was the result of development of in vitro resistance to piperacillin during therapy (four cases) and of underlying disease impairing host responses. Adverse reactions to piperacillin included leukopenia (eight cases) and nephrotoxicity (two cases).
Insights
Piperacillin effectively treated Pseudomonas aeruginosa infections initially, but resistance and underlying conditions led to relapses in some patients. Adverse effects like leukopenia and nephrotoxicity were observed.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Microbiology
Background:
- Piperacillin is a broad-spectrum semisynthetic penicillin derivative.
- Pseudomonas aeruginosa infections pose significant treatment challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin in treating Pseudomonas aeruginosa infections.
- To identify factors associated with treatment failure and adverse events.
Main Methods:
- A clinical study involving 22 patients with 25 Pseudomonas aeruginosa infections.
- Monitoring of clinical response, microbiologic eradication, and development of in vitro resistance.
- Assessment of adverse reactions.
Main Results:
- Initial favorable response observed in all patients.
- Microbiologic eradication achieved in 15 cases.
- Relapses occurred in complicated urinary tract infections and prosthesis-related infections.
- Treatment failure correlated with inability to eradicate P. aeruginosa due to acquired resistance (4 cases) or impaired host response.
- Observed adverse reactions included leukopenia (8 cases) and nephrotoxicity (2 cases).
Conclusions:
- Piperacillin demonstrates initial efficacy against Pseudomonas aeruginosa but is limited by the development of resistance and patient-specific factors.
- Careful patient selection and monitoring are crucial for optimizing piperacillin therapy.
- Further research into managing resistant Pseudomonas strains and supporting host defenses is warranted.